Calla Lily Clinical Care and Merck have entered a strategic collaboration to support the continued development of Callavid, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid technology. Callavid is a transformational leak-resistant medical device designed to address challenges associated with the self-administration of vaginal therapeutics.
Administration via the vaginal route can be associated with increased patient anxiety related to positioning, dosing accuracy, and concerns around leakage, particularly for certain therapeutics used in fertility treatments, oncology, and hormone therapies. Developed by the team at Calla Lily Clinical Care, Callavid's patented leak-free design delivers vaginal therapeutics using a small, tampon-shaped device combined with an integrated absorbent liner. Callavid is designed for hygienic insertion, remains in place during drug absorption, and can be easily and cleanly removed.
By supporting more consistent drug delivery and reducing concerns around leakage and positioning, Callavid is uniquely designed to improve the overall patient experience when administering vaginal medications.
